Mild side effects can occur with Ingrezza use. This list doesn’t include all possible mild side effects of the drug. For more information, you can refer to Ingrezza’s prescribing information.

Chief executive Kevin Gorman didn’t disclose Ingrezza’s price today, but this will be revealed ahead of its launch on 1 May. There are more major milestones ahead for the San Diego-based ...

Management proffered guidance for Ingrezza sales of $2.5 billion to $2.6 billion this year, which wouldn't represent hot growth over the 2024 tally of $2.3 billion. Both Guggenheim's Yatin Suneja ...

Neurocrine Biosciences (Nasdaq: NBIX) has announced positive results from its Phase IV KINECT-PRO study, showing that ...

Neurocrine Biosciences Q4 EPS of $1.69 beat estimates, while revenue missed consensus. Ingrezza sales rose 23% to $615 million. 2025 Ingrezza sales guidance fell short of Street estimate.

The firm sees potential upside for Neurocrine shares with multiple commercial products, including Ingrezza and Crenessity, and late stage programs in schizophrenia and depression, the analyst ...

Its flagship product, Ingrezza (valbenazine), is for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease. The company’s Crinecerfont recently obtained ...

Ingrezza treats tardive dyskinesia and chorea ... Crenessity is the first treatment that doesn't rely on glucocorticoids, which carry a host of side effects. Crenessity brought in $2 million ...

Overall, the quarter showcased strong performance, particularly from the flagship prescription medication Ingrezza, underscoring the effectiveness of its strategic initiatives. Neurocrine ...

JPMorgan lowered the firm’s price target on Neurocrine (NBIX) to $183 from $191 and keeps an Overweight rating on the shares. The firm updated ...